Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension
Completed · Phase 2
Conditions studied: Salt-sensitive Hypertension
In brief
This study will evaluate the effect of LCZ696 and valsartan on natriuresis, diuresis, and blood pressure in salt-sensitive Asian hypertensive patients.
Key facts
- Study ID
- NCT01681576
- Run by
- Novartis Pharmaceuticals
- People needed
- 72
- Starts
- 2012-08-01
- Expected to finish
- 2013-10-01
- Last updated by the study team
- 2015-11-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Anaheim, California, United States
- Novartis Investigative Site — Cypress, California, United States
- Novartis Investigative Site — Glendale, California, United States
- Novartis Investigative Site — Hong Kong, Shatin, NT, Hong Kong
- Novartis Investigative Site — Singapore, Singapore, Singapore
- Novartis Investigative Site — Singapore, Singapore, Singapore
- Novartis Investigative Site — Bucheon-si, Gyeonggi-do, South Korea
- Novartis Investigative Site — Koyang-si, Gyeonggi-do, South Korea
- Novartis Investigative Site — Seoul, Korea, South Korea
- Novartis Investigative Site — Seoul, South Korea
- Novartis Investigative Site — Seoul, South Korea
- Novartis Investigative Site — Taichung, Taiwan, Taiwan
- Novartis Investigative Site — Taipei, Taiwan, Taiwan
- Novartis Investigative Site — Taipei, Taiwan, Taiwan
- Novartis Investigative Site — Taipei, Taiwan, ROC, Taiwan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.